# hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma

> **NCT00082758** · PHASE2 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 39 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **BIOLOGICAL:** hu14.18-Interleukin-2 fusion protein

## Key facts

- **NCT ID:** NCT00082758
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2008-02
- **Final completion:** 2012-05
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2015-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00082758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00082758, "hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00082758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*